These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29126030)

  • 1. Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial.
    Zandi-Esfahan S; Fazeli M; Shaygannejad V; Hasheminia J; Badihian S; Aghayerashti M; Maghzi H
    Clin Neurol Neurosurg; 2017 Dec; 163():173-178. PubMed ID: 29126030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
    J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
    Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
    Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
    Orefice NS; Alhouayek M; Carotenuto A; Montella S; Barbato F; Comelli A; Calignano A; Muccioli GG; Orefice G
    Neurotherapeutics; 2016 Apr; 13(2):428-38. PubMed ID: 26857391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
    Ramirez-Ramirez V; Macias-Islas MA; Ortiz GG; Pacheco-Moises F; Torres-Sanchez ED; Sorto-Gomez TE; Cruz-Ramos JA; Orozco-Aviña G; Celis de la Rosa AJ
    Oxid Med Cell Longev; 2013; 2013():709493. PubMed ID: 23861993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of retinyl-palmitate on the level of pro and anti-inflammatory cytokines in multiple sclerosis patients: A randomized double blind clinical trial.
    Bitarafan S; Mohammadpour Z; Jafarirad S; Harirchian MH; Yekaninejad MS; Saboor-Yaraghi AA
    Clin Neurol Neurosurg; 2019 Feb; 177():101-105. PubMed ID: 30640138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
    Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
    Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
    De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
    Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory and therapeutic effects of Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients.
    Rezapour-Firouzi S; Arefhosseini SR; Mehdi F; Mehrangiz EM; Baradaran B; Sadeghihokmabad E; Mostafaei S; Fazljou SM; Torbati MA; Sanaie S; Zamani F
    Complement Ther Med; 2013 Oct; 21(5):473-80. PubMed ID: 24050582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
    Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    Koda T; Namba A; Nakatsuji Y; Niino M; Miyazaki Y; Sugimoto T; Kinoshita M; Takata K; Yamashita K; Shimizu M; Fukazawa T; Kumanogoh A; Mochizuki H; Okuno T
    PLoS One; 2018; 13(3):e0193986. PubMed ID: 29518148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
    Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
    Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.